NCT06854276View on ClinicalTrials.gov

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Chemotherapy-induced AnemiaNon-myeloid Malignancies
Interventions
DRUG

SSS06

SSS06 is a highly glycosylated, long-acting recombinant protein product produced through recombinant gene technology by introducing site-specific mutations into the rHuEPO gene.

DRUG

rhEPO

a recombinant human erythropoietin injection.

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY